Description
CISPLATIN AQ INJECTION
First action · last action
2011-12-16 · 2013-04-23
Transactions
2
First transaction's obligation
$551
Base + all options value (sum of deltas)
$446
Extent competed
COMPETED UNDER SAP
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
446110 · PHARMACIES AND DRUG STORES
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2011-12-16+$551= $551
- Mod P000012013-04-23-$105= $446
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2011-12-16 | +$551 | $551 | CISPLATIN AQ INJECTION |
| Mod P00001· CLOSE OUT | 2013-04-23 | −$105 | $446 | CISPLATIN AQ INJECTION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI S1RUKWWRYFL6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24126F0121 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $16,333 | FY2026 |
| 36C24226P0805 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $16,333 | FY2026 |
| 36C24026K1010 | VHA CHIEF LOGISTICS OFFICE (36C240) · 6505 · DRUGS AND BIOLOGICALS | $1,194,619,137 | FY2026 |
| 36C24026K1009 | VHA CHIEF LOGISTICS OFFICE (36C240) · 6505 · DRUGS AND BIOLOGICALS | $1,191,973,258 | FY2026 |
| 36C26226P1049 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $220,957 | FY2026 |
| 36C24026K1008 | VHA CHIEF LOGISTICS OFFICE (36C240) · 6505 · DRUGS AND BIOLOGICALS | $1,398,025,092 | FY2026 |
Other recipients under 6505 from 502-ALEXANDRIA (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25613P0654 | PROVEN PHARMACEUTICALS LLC | 502-ALEXANDRIA | $26,037 | FY2013 |
| VA25613P0146 | MCKESSON PLASMA AND BIOLOGICS LLC | 502-ALEXANDRIA | $26,439 | FY2013 |
| VA25612F1697 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 502-ALEXANDRIA | $75,238 | FY2012 |
| VA25612J1372 | CEPHEID | 502-ALEXANDRIA | $24,754 | FY2012 |
| VA25612P0311 | FRESENIUS KABI USA, LLC | 502-ALEXANDRIA | $3,992 | FY2012 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25612P0531_3600_-NONE-_-NONE- · retrieved 2026-09-26.